Quarterly Report (10-q)

0001577445 false --12-31 2021 Q3 0001577445 2021-01-01 2021-09-30 0001577445 2021-11-15 0001577445 2021-09-30 0001577445 2020-12-31 0001577445 2020-01-01 2020-09-30 0001577445 2021-07-01 2021-09-30 0001577445 2020-07-01 2020-09-30 0001577445 us-gaap:CommonStockMember 2020-12-31 0001577445 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001577445 us-gaap:RetainedEarningsMember 2020-12-31 0001577445 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001577445 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001577445 us-gaap:CommonStockMember 2021-09-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001577445 us-gaap:RetainedEarningsMember 2021-09-30 0001577445 us-gaap:CommonStockMember 2021-06-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001577445 us-gaap:RetainedEarningsMember 2021-06-30 0001577445 2021-06-30 0001577445 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001577445 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001577445 us-gaap:CommonStockMember 2019-12-31 0001577445 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001577445 us-gaap:RetainedEarningsMember 2019-12-31 0001577445 2019-12-31 0001577445 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001577445 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001577445 us-gaap:CommonStockMember 2020-09-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001577445 us-gaap:RetainedEarningsMember 2020-09-30 0001577445 2020-09-30 0001577445 us-gaap:CommonStockMember 2020-06-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001577445 us-gaap:RetainedEarningsMember 2020-06-30 0001577445 2020-06-30 0001577445 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001577445 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001577445 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001577445 SCTC:MedigusLtdMember 2019-01-03 0001577445 SCTC:MedigusLtdMember 2019-03-31 0001577445 SCTC:SecuritiesExchangeAgreementMember SCTC:ScoutCamLtdMember 2019-09-15 2019-09-16 0001577445 SCTC:SecuritiesExchangeAgreementMember SCTC:ScoutCamLtdMember 2019-09-16 0001577445 SCTC:SecuritiesExchangeAgreementMember SCTC:MedigusMember 2021-09-30 0001577445 2021-08-08 2021-08-09 0001577445 SCTC:LeaseAgreementMember 2021-01-01 2021-09-30 0001577445 SCTC:LeaseAgreementMember 2021-01-01 2021-01-02 0001577445 2019-12-01 2019-12-31 0001577445 SCTC:EachWarrantAMember 2021-09-30 0001577445 SCTC:EachWarrantBMember 2021-09-30 0001577445 SCTC:ConsultantMember 2021-01-01 2021-09-30 0001577445 SCTC:ConsultantMember srt:MaximumMember 2021-01-01 2021-09-30 0001577445 SCTC:ConsultantMember 2021-09-30 0001577445 SCTC:EachWarrantAMember 2020-01-01 2020-12-31 0001577445 SCTC:EachWarrantAMember 2020-12-30 0001577445 SCTC:EachWarrantBMember 2021-01-01 2021-06-30 0001577445 SCTC:EachWarrantBMember 2021-06-30 0001577445 us-gaap:WarrantMember 2020-03-02 2020-03-03 0001577445 us-gaap:WarrantMember 2020-03-03 0001577445 SCTC:WarrantAMember 2020-03-03 0001577445 SCTC:WarrantBMember 2020-03-03 0001577445 us-gaap:WarrantMember 2020-05-17 2020-05-18 0001577445 us-gaap:WarrantMember 2020-05-18 0001577445 SCTC:EachWarrantAMember 2020-05-18 0001577445 SCTC:EachWarrantBMember 2020-05-18 0001577445 SCTC:WarrantAMember 2021-02-01 2021-02-28 0001577445 SCTC:WarrantAMember us-gaap:SubsequentEventMember 2021-11-29 2021-11-30 0001577445 SCTC:LetterAgreementMember SCTC:MedigusLtdMember 2020-06-23 0001577445 SCTC:LetterAgreementMember SCTC:MedigusLtdMember us-gaap:CommonStockMember 2020-06-21 2020-06-23 0001577445 SCTC:LetterAgreementMember SCTC:MedigusLtdMember SCTC:WarrantAMember 2020-06-23 0001577445 SCTC:LetterAgreementMember SCTC:MedigusLtdMember SCTC:WarrantBMember 2020-06-23 0001577445 SCTC:EachWarrantAMember 2020-06-23 0001577445 SCTC:EachWarrantBMember 2020-06-23 0001577445 SCTC:InvestorsMember 2021-03-21 2021-03-22 0001577445 SCTC:InvestorsMember 2021-03-22 0001577445 SCTC:WarrantAMember 2021-01-01 2021-09-30 0001577445 SCTC:WarrantAMember 2021-09-30 0001577445 SCTC:WarrantBMember 2021-01-01 2021-09-30 0001577445 SCTC:WarrantBMember 2021-09-30 0001577445 SCTC:WarrantBOneMember 2021-01-01 2021-09-30 0001577445 SCTC:WarrantBOneMember 2021-09-30 0001577445 SCTC:WarrantMarchTwoThousandTwentyOneMember 2021-01-01 2021-09-30 0001577445 SCTC:WarrantMarchTwoThousandTwentyOneMember 2021-09-30 0001577445 us-gaap:WarrantMember 2021-09-30 0001577445 SCTC:MedigusLtdMember SCTC:ExchangeAgreementMember 2021-01-01 2021-09-30 0001577445 SCTC:MedigusLtdMember SCTC:ExchangeAgreementMember 2021-09-30 0001577445 SCTC:TwoThousandAndTwentyShareIncentivePlanMember SCTC:EmployeesConsultantsDirectorsAndOtherServiceProvidersMember 2020-02-01 2020-02-29 0001577445 SCTC:TwoThousandAndTwentyShareIncentivePlanMember SCTC:BoardOfDirectorsMember 2020-03-14 2020-03-15 0001577445 SCTC:TwoThousandAndTwentyShareIncentivePlanMember SCTC:BoardOfDirectorsMember 2020-06-21 2020-06-22 0001577445 SCTC:TwoThousandAndTwentyShareIncentivePlanMember SCTC:BoardOfDirectorsMember 2021-01-01 2021-06-30 0001577445 SCTC:TwoThousandAndTwentyShareIncentivePlanMember 2021-01-01 2021-09-30 0001577445 srt:MinimumMember 2021-09-30 0001577445 srt:MaximumMember 2021-09-30 0001577445 srt:MinimumMember 2021-01-01 2021-09-30 0001577445 srt:MaximumMember 2021-01-01 2021-09-30 0001577445 us-gaap:CostOfSalesMember 2021-01-01 2021-09-30 0001577445 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001577445 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-09-30 0001577445 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001577445 SCTC:MedigusLtdMember SCTC:IntercompanyAgreementMember 2019-05-29 2019-05-30 0001577445 SCTC:MedigusLtdMember SCTC:AmendedAndRestatedIntercompanyServicesAgreementMember 2020-04-19 2020-04-20 0001577445 SCTC:MedigusLtdMember 2021-09-30 0001577445 SCTC:MedigusLtdMember 2020-12-31 0001577445 SCTC:MedigusLtdMember 2021-01-01 2021-09-30 0001577445 SCTC:MedigusLtdMember 2020-01-01 2020-09-30 0001577445 2021-09-29 2021-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:ILS

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 333-188920

SCOUTCAM INC.

(Exact name of registrant as specified in its charter)

Nevada

47-4257143

(State or other jurisdiction

of incorporation or organization)

(I.R.S. Employer

Identification No.)

Suite 7A, Industrial Park
P.O. Box 3030, Omer, Israel		8496500
(Address of Principal Executive Offices)		(Zip Code)

+972 73 370-4691

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

☐	Large accelerated filer	☐	Accelerated filer
☒	Non-accelerated filer	☒	Smaller reporting company
		☐	Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 15, 2021, the registrant had 7,121,737 shares of common stock, par value $0.001, of the registrant issued and outstanding.

As used in this Quarterly Report and unless otherwise indicated, the terms “ScoutCam,” “we,” “us,” “our,” or “our Company” refer to ScoutCam Inc. Unless otherwise specified, all dollar amounts are expressed in United States dollars.

SCOUTCAM INC.

QUARTERLY REPORT ON FORM 10-Q

TABLE OF CONTENTS

		Page

Cautionary Note Regarding Forward-Looking Statements		3

PART 1-FINANCIAL INFORMATION

Item 1.	Consolidated Financial Statements (unaudited)	4

	Consolidated Balance Sheets	5

	Consolidated Statements of Comprehensive Loss	7

	Statements of Stockholders’ Equity	8

	Consolidated Statements of Cash Flows	10

	Notes to Consolidated Financial Statements	11

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	25

Item 4.	Control and Procedures	25

PART II-OTHER INFORMATION

Item 1A.	Risk Factors	26

Item 6.	Exhibits	26

SIGNATURES		27

- 2 -

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain information set forth in this Quarterly Report on Form 10-Q, including in Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere herein may address or relate to future events and expectations and as such constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events.

Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. These statements may be found under the section of our Annual Report on Form 10-K for the year ended December 31, 2020 (filed on March 31, 2021) entitled “Risk Factors” as well as in our other public filings.

In light of these risks and uncertainties, and especially given the start-up nature of our business, there can be no assurance that the forward-looking statements contained herein will in fact occur. Readers should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

On August 9, 2021, we filed an amendment to our Articles of Incorporation in order to effect a one-for-nine reverse stock split of our common stock, par value $0.001 per share (the “Common Stock”) pursuant to which holders of our Common Stock received one share of our Common Stock for every nine shares of Common Stock held. Unless the context expressly dictates otherwise, all references to share and per share amounts referred to herein reflect the reverse stock split.

- 3 -

Item 1. Financial Statements

ScoutCam INC.

INTERIM FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2021

CONSOLIDATED SCOUTCAM INC.

	Page
Interim Condensed Consolidated Financial Statements - in US Dollars (USD) in thousands
Interim Condensed Consolidated Balance Sheets (unaudited)	5
Interim Condensed Consolidated Statements of Operations (unaudited)	7
Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity (unaudited)	8
Interim Condensed Consolidated Statements of Cash Flows (unaudited)	10
Notes to the Interim Condensed Consolidated Financial Statements	11

- 4 -

SCOUTCAM INC.

INTERIM CONDENSED CONSOLIATED BALANCE SHEETS

	September 30,		December 31,
	2021		2020
	Unaudited		Audited
	USD in thousands
Assets

CURRENT ASSETS:
Cash and cash equivalents		19,725		3,373
Accounts receivable		19		17
Inventory		145		244
Medigus receivable		-		47
Other current assets		537		348
Total current assets		20,426		4,029
NON-CURRENT ASSETS:
Contract fulfillment assets		1,634		1,130
Property and equipment, net		720		269
Operating lease right-of-use assets		406		107
Severance pay asset		416		360
Total non-current assets		3,176		1,866

TOTAL ASSETS		23,602		5,895

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

- 5 -

SCOUTCAM INC.

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)

	September 30,			December 31,
	2021			2020
	Unaudited			Audited
	USD in thousands
Liabilities and shareholders’ equity

CURRENT LIABILITIES:
Accounts payables		201			79
Contract liabilities		-			69
Operating lease liabilities - short term		222			60
Accrued compensation expenses		403			369
Medigus payable		25			-
Other accrued expenses		255			195
Total current liabilities		1,106			772
NON-CURRENT LIABILITIES:
Contract liabilities		1,377			779
Operating lease liabilities - long term		184			47
Liability for severance pay		333			333
Total non-current liabilities		1,894			1,159
TOTAL LIABILITIES		3,000			1,931

SHAREHOLDERS’ EQUITY:
Common stock, $0.001 par value; 300,000,000 and 75,000,000 shares authorized as of September 30, 2021 and December 31, 2020, 6,929,517 and 4,084,122 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively		7			4
Additional paid-in capital		33,158			10,267
Accumulated deficit		(12,563	)		(6,307	)
TOTAL SHAREHOLDERS’ EQUITY		20,602			3,964

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		23,602			5,895

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

- 6 -

SCOUTCAM INC.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS


	Nine months ended						Three months ended
	September 30,						September 30,
	2021			2020			2021			2020
	Unaudited
	USD in thousands (except per share data)

Revenues – Products		321			86			23			12
Cost of revenues – Products		821			434			211			153
Gross Loss		(500	)		(348	)		(188	)		(141	)
Research and development expenses		1,350			514			596			144
Sales and marketing expenses		472			302			179			114
General and administrative expenses		3,931			2,309			1,603			629
Other income		3			-			3			-
Operating loss		(6,250	)		(3,473	)		(2,563	)		(1,028	)
Financing income (expenses), net		(6	)		63			1			1
Loss before taxes on income		(6,256	)		(3,410	)		(2,562	)		(1,027	)
Taxes on income		-			-			-			-
Net Loss		(6,256	)		(3,410	)		(2,562	)		(1,027	)
Net loss per ordinary share (basic and diluted, USD)		(1.05	)		(1.00	)		(0.37	)		(0.27	)
Weighted average ordinary shares (basic and diluted, in thousands)		5,968			3,414			6,930			3,752

- 7 -

SCOUTCAM INC.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

Nine Months Ended September 30, 2021 (Unaudited)


	Ordinary shares				Additional paid-in		Accumulated			Total Shareholders’
	Number		Amount		capital		deficit			equity
	In thousands		USD in thousands
Balance at January 1, 2021		4,084		4		10,267		(6,307	)		3,964
Issuance of shares and warrants		2,469		2		19,116		-			19,118
Stock based compensation		-		-		1,317		-			1,317
Exercise of warrants		375		1		2,458		-			2,459
Round up shares due to reverse stock split		1		*		-		-			-
Conversion of a loan from Medigus
Conversion of a loan from Medigus, shares
Net loss		-		-		-		(6,256	)		(6,256	)

Balance at September 30, 2021		6,929		7		33,158		(12,563	)		20,602

Three Months Ended September 30, 2021 (Unaudited)

	Ordinary shares				Additional paid-in		Accumulated			Total Shareholders’
	Number		Amount		capital		deficit			Equity
	In thousands		USD in thousands
Balance at July 1, 2021		6,929		7		32,476		(10,001	)		22,482
Stock based compensation		-		-		682		-			682
Net loss		-		-		-		(2,562	)		(2,562	)

Balance at September 30, 2021		6,929		7		33,158		(12,563	)		20,602

*	Represents an amount less than $1 thousand

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

- 8 -

Nine Months Ended September 30, 2020 (Unaudited)

	Ordinary shares				Additional paid-in		Accumulated			Total Shareholders’
	Number		Amount		capital		deficit			Equity
	in thousands		USD in thousands
Balance at January 1, 2020		2,987		3		4,159		(1,640	)		2,522
Issuance of shares and warrants		677		1		2,857		-			2,858
Stock based compensation		-		-		961		-			961
Conversion of a loan from Medigus		87		*		381		-			381
Net loss		-		-		-		(3,410	)		(3,410	)

Balance at September 30, 2020		3,751		4		8,358		(5,050	)		3,312

Three Months Ended September 30, 2020 (Unaudited)

	Ordinary shares				Additional paid-in		Accumulated			Total Shareholders’
	Number		Amount		capital		deficit			Equity
	in thousands		USD in thousands
Balance at July 1, 2020		3,751		4		8,268		(4,023	)		4,249
Stock based compensation		-		-		90		-			90
Net loss		-		-		-		(1,027	)		(1,027	)

Balance at September 30, 2020		3,751		4		8,358		(5,050	)		3,312

*	Represents an amount less than $1 thousand

- 9 -

SCOUTCAM INC.

INTERIM CONDENSED CONOLIDATED STATEMENTS OF CASH FLOWS

	2021			2020			2021			2020
	Nine months ended						Three months ended
	September 30,						September 30,
	2021			2020			2021			2020
	Unaudited
	USD in thousands

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		(6,256	)		(3,410	)		(2,562	)		(1,027	)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation		63			51			24			24
Other non-cash items		(56	)		1			-			(13	)
Share based compensation		1,317			927			682			90
Profit from exchange differences on cash and cash equivalents		(12	)		(87	)		(8	)		(3	)

CHANGES IN OPERATING ASSET AND LIABILITY ITEMS:
Accounts receivable		(2	)		22			41			26
Inventory		99			(546	)		-			(244	)
Medigus receivable / payable		72			2			12			113
Other current assets		(170	)		(199	)		203			55
Accounts payable		122			146			(102	)		13
Contract fulfilment assets		(504	)		-			(124	)		-
Contract liabilities		529			699			(8	)		529
Accrued compensation expenses		34			78			(26	)		42
Other accrued expenses		60			(394	)		82			(38	)
Net cash flows used in operating activities		(4,704	)		(2,710	)		(1,786	)		(433	)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of property and equipment		(483	)		(249	)		(177	)		(28	)
Net cash flows used in investing activities		(483	)		(249	)		(177	)		(28	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Loan repayment to Medigus		-			(81	)		-			-
Issuance expenses		(50	)		-			(95	)		-
Proceeds from exercise of warrants		2,459			-			-			-
Proceeds from issuance of shares and warrants		19,118			2,858			-			-
Net cash flows provided by (used in) financing activities		21,527			2,777			(95	)		-

INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		16,340			(182	)		(2,058	)		(461	)
BALANCE OF CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD		3,373			3,245			21,775			3,608
PROFIT FROM EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS		12			87			8			3
BALANCE OF CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD		19,725			3,150			19,725			3,150

Non cash activities -

	Nine months ended				Three months ended
	September 30,				September 30,
	2021		2020		2021		2020
	Unaudited
	USD in thousands
Non cash activities -
Right-of-use assets obtained in exchange for operating lease liabilities		423		90		64		61
Increase in property and equipment through a decrease in advances to suppliers		31		-		167		-
Medigus loan settled against Medigus receivable		-		41		-		-
Conversion of a loan from Medigus		-		381		-		-

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

- 10 -

SCOUTCAM INC.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – GENERAL:

ScoutCam Inc. (the “Company”), formerly known as Intellisense Solutions Inc., (“Intellisense”), was incorporated under the laws of the State of Nevada on March 22, 2013. The Company was initially engaged in the business of developing web portals to allow companies and individuals to engage in the purchase and sale of vegetarian food products over the Internet. The Company was unable to execute its original business plan, develop significant operations or achieve commercial sales. Prior to the closing of the Securities Exchange Agreement (as defined below), the Company was a “shell company”.

ScoutCam Ltd. (“ScoutCam”), was formed in the State of Israel on January 3, 2019 as a wholly-owned subsidiary of Medigus Ltd. (“Medigus”), an Israeli company traded on the Nasdaq Capital Market, and commenced operations on March 1, 2019. Upon incorporation, ScoutCam issued to Medigus 1,000,000 Ordinary shares with no par value. On March 2019, ScoutCam issued to Medigus an additional 1,000,000 Ordinary shares with no par value.

ScoutCam was incorporated as part of a reorganization of Medigus, which was designed to distinguish ScoutCam’s miniaturized imaging business, or the micro ScoutCam™ portfolio, from Medigus’s other operations and to enable Medigus to form a separate business unit with dedicated resources focused on the promotion of such technology. In December 2019, Medigus and ScoutCam consummated a certain Amended and Restated Asset Transfer Agreement, under which Medigus transferred and assigned certain assets and intellectual property rights related to its miniaturized imaging business to ScoutCam.

On September 16, 2019, Intellisense entered into a Securities Exchange Agreement (the “Exchange Agreement”), with Medigus, pursuant to which Medigus assigned, transferred and delivered 100% of its holdings in ScoutCam to Intellisense, in exchange for consideration consisting of shares of Intellisense’s common stock representing 60% of the issued and outstanding share capital of Intellisense immediately upon the closing of the Exchange Agreement (the “Closing”). The Closing occurred on December 30, 2019 (the “Closing Date”).

Although the transaction resulted in ScoutCam becoming a wholly owned subsidiary of Intellisense, the transaction constituted a reverse recapitalization since Medigus, the only shareholder of ScoutCam prior to the Exchange Agreement, was issued a substantial majority of the outstanding capital stock of Intellisense upon consummation of the Exchange Agreement, and also taking into account that prior to the Closing Date, Intellisense was considered as a shell corporation. Accordingly, ScoutCam is considered the accounting acquirer of the merged company.

As of September 30, 2021, Medigus holds approximately 28% of the Company.

“Group” – the Company together with ScoutCam.

ScoutCam is a leading provider of image-based platforms. Pioneering the use of its proprietary visualization technology, ScoutCam offers state-of-the-art solutions across a variety of Predictive Maintenance and Condition Based Monitoring markets, thus paving the way for the energy, automotive and aviation industries. ScoutCam’s solutions are based on small and highly resilient cameras, specialized AI analysis and supplementary technologies.

- 11 -

SCOUTCAM INC.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – GENERAL (continued):

	b.	On August 9, 2021, the Company amended its Articles of Incorporation to effect a 9 to 1 reverse stock split of the Company’s outstanding Common Stock. As a result of the reverse stock split, every 9 shares of the Company’s outstanding Common Stock prior to the effect of that amendment was combined and reclassified into one share of the Company’s Common Stock. No fractional shares were issued in connection with or following the reverse split. The number of authorized capital of the Company’s Common Stock and par value of the shares remained unchanged. All share, stock option and per share information in these condensed consolidated financial statements have been adjusted to reflect the stock split on a retroactive basis.

	c.	Since incorporation and through September 30, 2021, the Group has an accumulated deficit of approximately $12.6 million and its activities have been funded mainly by its shareholders. The Company’s management believes the Group’s cash and cash resources as of September 30, 2021, will allow the Group to fund its operating plan for more than 12 months from the date of issuance of these financial statements. However, the Group expects to continue to incur significant research and development and other costs related to its ongoing operations and in order to continue its future operations, the Group will need to obtain additional funding until becoming profitable.

	d.	In early 2020, the World Health Organization declared the rapidly spreading coronavirus disease (COVID-19) outbreak a pandemic. This pandemic has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. The Group considered the impact of COVID-19 on its operations and determined that there were no material adverse impacts on the Group’s results of operations and financial position as of September 30, 2021. These estimates may change, as new events occur and additional information is obtained.

NOTE 2 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Unaudited Interim Financial Statements

The accompanying unaudited interim condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Group’s Annual Report on Form 10-K for the year ended December 31, 2020.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.

Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, deferred taxes, inventory impairment, stock based compensation, as well as in estimates used in applying the revenue recognition policy. Actual results may differ from those estimates.

Significant Accounting Policies

The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements.

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Group’s condensed consolidated financial statements.

- 12 -

SCOUTCAM INC.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 3 – LEASES:

ScoutCam leases office and vehicles under operating leases. On September 30, 2021, the Group’s ROU assets and lease liabilities for operating leases totaled $406 thousand.

In December 2020, ScoutCam entered into a lease agreement for office space in Omer, Israel. The agreement is for 36 months beginning on January 1, 2021. ScoutCam holds the right to terminate the lease agreement after 24 months. In March 2021, ScoutCam entered into a lease agreement for additional office space in Omer, Israel. The agreement is until December 31, 2023. ScoutCam holds the right to terminate these agreements by December 31, 2022. Monthly lease payments under the agreements are approximately $12 thousand.

Lease expenses recorded in the interim consolidated statements of operations were $133 thousand for the nine months ended September 30, 2021.

ScoutCam subleases the part of the office space to a third party for approximately $3 thousand for month.

Supplemental cash flow information related to operating leases was as follows:

	Nine months ended 30, 2021
	USD in thousands
Cash payments for operating leases		133
Total lease expenses		133

As of September 30, 2021, the Company’s operating leases had a weighted average remaining lease term of 1.53 years and a weighted average discount rate of 10%. Future lease payments under operating leases as of September 30, 2021 were as follows:

	Operating leases
	USD in thousands
Remainder of 2021		61
2022		223
2023		165
2024		3
Total future lease payments		452
Less imputed interest		(46	)
Total lease liability balance		406

- 13 -

SCOUTCAM INC.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 – EQUITY:

Private placement:

In December 2019, the Company allocated in a private issuance, a total of 379,269 units at a purchase price of USD $8.712 per unit. Each unit was comprised of two shares of common stock par value US$0.001 per share, one Warrant A (defined below) and two Warrants B (defined below). The immediate proceeds (gross) from the issuance of the units amounted to approximately USD 3.3 million.

Each Warrant A was exercisable into one share of common stock of the Company at an exercise price of USD 5.355 per share during the 12 month period following the allocation. Each Warrant B is exercisable into one share of common stock of the Company at an exercise price of USD 8.037 per share during the 18 month period following the allocation.

In addition, Shrem Zilberman Group Ltd. (the “Consultant”) was entitled to receive the amount representing 3% of any exercise price of each Warrant A or Warrant B that may be exercised in the future. In the event the total proceeds received as a result of exercise of Warrants will be less than $2 million at the time of their expiration, the Consultant will be required to invest $250,000 in the Company in return for shares of common stock of Company. As of September 30, 2021, holders of the foregoing warrants have exercised in excess of $2 million and, accordingly, the Consultant is not required to invest $250,000 in the Company.

During 2020, 332,551 Warrants A were exercised. 46,718 unexercised Warrants A expired on December 30, 2020.

During the second quarter of 2021, 185,271 Warrants B were exercised. 573,256 unexercised Warrants B expired on June 30, 2021.

On March 3, 2020, the Company issued in a private issuance a total of 108,880 units at a purchase price of USD 8.712 per unit.

Each unit was comprised of two shares of common stock par value US$0.001 per share, one Warrant A (defined below) and two Warrants B (defined below).

Each Warrant A was exercisable into one share of common stock of the Company at an exercise price of USD 5.355 per share during the 12 month period following the allocation.

Each Warrant B is exercisable into one share of common stock of the Company at an exercise price of USD 8.037 per share during the 18 month period following the allocation.

The gross proceeds from the issuance of all securities offered amounted to approximately USD 948 thousands. After deducting issuance costs, the Company received proceeds of approximately USD 909 thousand.

During 2021, all Warrants A were exercised.

On September 3, 2021 all Warrants B were expired.

On May 18, 2020, the Company allocated in a private issuance a total of 229,569 units at a purchase price of USD 8.712 per unit.

Each unit was comprised of two shares of common stock par value US$0.001 per share, one Warrant A (defined below) and two Warrants B (defined below).

Each Warrant A is exercisable into one share of common stock of the Company at an exercise price of USD 5.355 per share during the 18 month period following the allocation.

Each Warrant B is exercisable into one share of common stock of the Company at an exercise price of USD 8.037 per share during the 24 month period following the allocation.

- 14 -

SCOUTCAM INC.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 – EQUITY (continued):

The gross proceeds from the issuance of all securities offered amounted to approximately USD 2 million. After deducting issuance costs, the Company received proceeds of approximately USD 1.9 million.

During February 2021, 37,349 Warrants A were exercised.

During November 2021, 192,220 Warrants A were exercised.

On June 23, 2020, (the “Conversion Date”), the Company entered into and consummated a Side Letter Agreement with Medigus, whereby the parties agreed to convert, at a conversion price of $4.356, an outstanding line of credit previously extended by Medigus to the ScoutCam, which as of the Conversion Date was $381,136, into (a) 87,497 shares of the Company’s common stock, (b) warrants to purchase 43,749 shares of common stock with an exercise price of $5.355 (Warrant A), and (c) warrants to purchase 87,497 shares of common stock with an exercise price of $8.037 (Warrant B). As the conversion price represented the same unit price as in the March 2020 and May 2020 private placements, no finance expenses have been recorded in statement of operations as a result of the conversion.

Each Warrant A is exercisable into one share of common stock of the Company at an exercise price of USD 5.355 per share during the 12 months period following the allocation.

Each Warrant B is exercisable into one share of common stock of the Company at an exercise price of USD 8.037 per share during the 18 months period following the allocation.

During June 2021, all Warrants A were exercised.

On March 22, 2021, the Company undertook to issue to certain investors (the “Investors”) 2,469,156 units (the “Units”) in exchange for an aggregate purchase price of $20 million. Each Unit consists of (i) one share of the Company’s common stock and (ii) one warrant to purchase one share of common stock with an exercise price of USD 10.35 per share (the “Warrant March 2021” and the “Exercise Price”). Each Warrant is exercisable until the close of business on March 31, 2026.

Pursuant to the terms of the Warrant March 2021, following April 1, 2024, if the closing price of the common stock equals or exceeds 135% of the Exercise Price (subject to appropriate adjustments for stock splits, stock dividends, stock combinations and other similar transactions after the issue date of the Warrants) for any thirty (30) consecutive trading days, the Company may force the exercise of the Warrants, in whole or in part, by delivering to the Investors a notice of forced exercise.

As of September 30, 2021, the Company had the following outstanding warrants to purchase common stock:

Warrant

Issuance Date

Expiration Date

Exercise Price

Per Share ($)

Number of

Shares

of common

stock

Underlying

Warrants

Warrant A

May 18, 2020

November 18, 2021

5.355

192,220

Warrant B

May 18, 2020

May 18, 2022

8.037

459,137

Warrant B

June 23, 2020

December 23, 2021

8.037

87,497

Warrant March 2021

March 29, 2021

March 31, 2026

10.350

2,469,156

3,208,010

In additional, If ScoutCam achieves an aggregate amount of $33 million in sales within the first three years immediately after the Exchange Agreement, the Company will issue to Medigus 298,722 shares of the Company’s common stock, which represents 10% of the Company’s issued and outstanding share capital as of the Exchange Agreement.

- 15 -

SCOUTCAM INC.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 – EQUITY (continued):

Share-based compensation to employees, directors and service providers:

In February 2020, the Company’s Board of Directors approved the 2020 Share Incentive Plan (the “Plan”). The Plan initially included a pool of 580,890 shares of common stock for grant to Company employees, consultants, directors and other service providers. On March 15, 2020, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan by an additional 64,099 shares of Common Stock. On June 22, 2020, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan by an additional 401,950 shares of common stock. During the second quarter of 2021, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan by an additional 777,778 shares of common stock.

The Plan is designed to enable the Company to grant options to purchase ordinary shares and RSUs under various and different tax regimes including, without limitation: (i) pursuant and subject to Section 102 of the Israeli Tax Ordinance or any provision which may amend or replace it and any regulations, rules, orders or procedures promulgated thereunder and to designate them as either grants made through a trustee or not through a trustee; and (ii) pursuant and subject to Section 3(i) of the Israeli Tax Ordinance.

During the nine months ended September 30, 2021, the Company granted 583,712 options pursuant to the Plan.

The fair value of each option was estimated as of the date of grant or reporting period using the Black-Scholes option-pricing model, using the following assumptions:

	Nine months ended September 30, 2021
Underlying value of ordinary shares ($)		7.65-10.35
Exercise price ($)		2.61-7.20
Expected volatility (%)		45.80%-47.44	%
Term of the options (years)		7
Risk-free interest rate (%)		0.78%-1.13	%

The cost of the benefit embodied in the options granted during the nine months ended September 30, 2021, based on their fair value as at the grant date, is estimated to be approximately $3,909 thousands. These amounts will be recognized in statements of operations over the vesting period.

- 16 -

SCOUTCAM INC.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 – EQUITY (continued):

The following table summarizes stock option activity for the nine months ended September 30, 2021:

SCHEDULE OF STOCK OPTIONS ACTIVITY

	For the Nine months ended September 30, 2021
	Amount of options			Weighted average exercise price
				$
Outstanding at beginning of period		737,049			2.62
Granted		583,712			4.05
Cancelled		(109,506	)		2.82
Outstanding at end of period		1,211,255			3.28

Vested at end of period		373,332			2.61

The following table sets forth the total share-based payment expenses resulting from options granted, included in the statements of operation:

	Nine months ended September 30, 2021
	USD in thousands

Cost of revenues		26
Research and development		305
Sales and marketing		33
General and administrative		953
Total expenses		1,317

- 17 -

SCOUTCAM INC.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 5 – REVENUES:

Contract fulfillment assets and Contract liabilities:

The Company’s contract fulfillment assets and contract liabilities as of September 30, 2021 and December 31, 2020 were as follows:

SCHEDULE OF CONTRACT LIABILITIES

	September 30, 2021		December 31, 2020
	USD in thousands
Contract fulfillment assets		1,634		1,130
Contract liabilities		1,377		848

Remaining Performance Obligations

Remaining Performance Obligations (“RPO”) represents contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. As of September 30, 2021, the total RPO amounted to $2.7 million, which the Company expects to recognize over the expected manufacturing term of the product under development.

NOTE 6 – INVENTORY:

Composed as follows:

SCHEDULE OF INVENTORY

	September 30, 2021		December 31, 2020
	USD in thousands
Raw materials and supplies		145		45
Finished goods		-		278
Inventory write downs		-		(79	)
Inventory net		145		244

During the period ended September 30, 2021, no impairment occurred.

- 18 -

SCOUTCAM INC.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 7 – LOSS PER SHARE

Basic loss per share is computed by dividing net loss attributable to ordinary shareholders of the Company, by the weighted average number of ordinary shares as described below.

In computing the Company’s diluted loss per share, the numerator used in the basic loss per share computation is adjusted for the dilutive effect, if any, of the Company’s potential shares of common stock. The denominator for diluted loss per share is a computation of the weighted-average number of ordinary shares and the potential dilutive ordinary shares outstanding during the period.

NOTE 8 – RELATED PARTIES

On May 30, 2019, ScoutCam Ltd. entered into an intercompany agreement with Medigus (the “Intercompany Agreement”) according to which ScoutCam Ltd. agreed to hire and retain certain services from Medigus. The agreed upon services provided under the Intercompany Agreement included: (1) lease of office space and clean room based on actual space utilized by ScoutCam Ltd. and in shared spaces according to employee ratio; (2) utilities such as electricity water, IT and communication services based on employee ratio; (3) car services, including car rental, gas usage, payment for toll roads based on 100% of expense incurred from a ScoutCam Ltd. employee car; (4) external accountant services at a price of USD 6,000 per annum; (5) directors and officers insurance at a sum of 1/3 of Medigus cost; (6) CFO services at a sum of 50% of Medigus company CFO employer cost; (7) every direct expense of ScoutCam Ltd. that is paid by Medigus in its entirety subject to approval of such direct expenses in advance; and (8) any other mutual expense that is borne by the parties according to the Respective portion of the Mutual Expense

In addition, ScoutCam Ltd.’s employees provide support services to Medigus.

On April 20, 2020, ScoutCam Ltd. entered into an amended and restated intercompany services agreement with Medigus.

Balances with related Medigus:

	September 30, 2021		December 31, 2020
	USD in thousands

Medigus receivable		-		47
Medigus payable		25		-

Transactions with Medigus:

SCHEDULE OF RELATED PARTY TRANSACTIONS

	2021		2020
	Nine months ended September 30,
	2021		2020
	USD in thousands
Cost of revenues		-		4
Research and development expenses		-		5
General and administrative expenses		37		81

NOTE 9 – VAT AUDIT

On September 30, 2021, following a VAT audit in Israel for years 2019-2021, the Company is deemed to be in debt of approximately NIS 740 thousand, (which is approximately USD 229 thousand) additional taxes. Provision of USD 229 thousand was recorded in these financial statements. The company intends to submit an objection.

- 19 -

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Readers are advised to review the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2020. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements”. You should review the “Risk Factors” section of our Annual Report for the fiscal year ended December 31, 2020 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

The Company’s primary business activities during last few months were the completion of R&D in connection with a customer-specific project and the transition to the production stage with respect to a contract with a Fortune 500 Multinational Healthcare Corporation, and R&D activities in the domain of I4.0 (including Predictive Maintenance and CBM (Condition Based Monitoring) in sectors such as the Aviation, Energy and Automotive).

Other major activities were the following:

	-	expanding marketing activities, including the recruitment of a Director of Business Development in the US, and launching a multi-platform digital marketing campaign;
	-	extensive activity in connection with the Company’s IP, including submissions of new patent applications as well as maintenance, defense, and commercialization efforts of existing patents;
	-	increased operation expenses in order to improve the current Company’s R&D capabilities;
	-	increase in research and development activities, including the development of new products and the improvement of existing technology, and the examination of additional applications for our micro ScoutCam™ portfolio outside of the medical, defense and aerospace fields, including sectors such as, inter alia, automotive, industrial non-destructing-testing industries, and predictive maintenance (i.e. Industry 4.0) based on Internet of Things (IoT); and
	-	investment in capital expenses to provide the necessary facilities, IT, and lab tools for our newly recruited employees and to upgrade the Company’s production and quality control capabilities.

Comparison of the nine months ended September 30, 2021 and 2020

The following table summarizes our results of operations for the nine months period ended September 30, 2021, and 2020, together with the changes in those items in dollars and as a percentage:

	Nine months ended September 30,
	2021			2020			% Change
Revenues		321,000			86,000			273	%
Cost of Revenues		821,000			434,000			89	%
Gross Loss		(500,000	)		(348,000	)		44	%
Research and development expenses		1,350,000			514,000			163	%
Sales and marketing expense		472,000			302,000			56	%
General and administrative expenses		3,931,000			2,309,000			70	%
Other income		3,000			-			-
Operating Loss		(6,250,000	)		(3,473,000	)		80	%

- 20 -

Revenues

For the nine months ended September 30, 2021, we generated revenues of $321,000, an increase of $235,000 from the nine months ended September 30, 2020.

The increase in revenues was primarily due to revenues from A.M. Surgical. Total revenues recorded from A.M. Surgical during the nine months ended September 30, 2021 amounted to approximately $200,000. We did not record any revenue from A.M. Surgical during the nine months ended September 30, 2020.

Cost of Revenues

Cost of revenues for the nine months ended September 30, 2021 was $821,000, an increase of $387,000 compared to cost of revenues of $434,000 for the nine months ended September 30, 2020. The increase was primarily due to an increase in materials as a result of an increase in revenues and an increase in payroll expenses as a result of hiring additional employees as part of the transition to the production stage with respect to a contract with a Fortune 500 Multinational Healthcare Corporation.

Gross Loss

Gross loss for the nine months ended September 30, 2021, was $500,000, an increase of $152,000 compared to gross loss of $348,000 for the nine months ended September 30, 2020.

Research and Development Expenses

Research and development expenses for the nine months ended September 30, 2021 were $1,350,000, an increase of $836,000, or 163%, compared to $514,000 for the nine months ended September 30, 2020. The increase was primarily due to (i) an increase in payroll expenses and materials and subcontractors and (ii) an increase in research and development activities, including the development of new products and the improvement of existing technology. We recently begun examining additional applications for our micro ScoutCam™ portfolio outside of the medical, defense and aerospace fields, including sectors such as, inter alia, automotive, industrial non-destructing-testing industries, and predictive maintenance (i.e. Industry 4.0) based on Internet of Things (IoT). We plan to further expand the activity in these non-medical spaces.

We expect that our research and development expenses will increase as we continue to develop our products and service and recruit additional research and development employees to the I4.0 domain.

- 21 -

Sales and Marketing Expenses

Sales and marketing expenses for the nine months ended September 30, 2021, were $472,000, an increase of $170,000, or 56%, compared to $302,000 for the nine months ended September 30, 2020. The increase was primarily due to an expanding marketing activity, including the recruitment of a Director of Business Development in the US, and launching a multi-platform digital marketing campaign.

We expect that our selling and marketing expenses will increase as we continue to increase our selling and marketing efforts.

General and Administrative Expenses

General and Administrative expenses for the nine months ended September 30, 2021 were $3,931,000, an increase of $1,622,000, or 70%, compared to $2,309,000 for the nine months ended September 30, 2020. The increase was primarily due to:

	●	an increase of $616,000 in IP expenses due to maintenance, defense, and commercialization efforts of existing patents;
	●	the provision of $229,000 due to VAT audit as described in Note 9 of our interim condensed financial statements as of September 30, 2021;
	●	an increase of $151,000 in share based compensation due to new option grants as described in Note 4 of our interim condensed financial statements as of September 30, 2021;
	●	an increase in in payroll expenses due to the hiring of additional employees including a new CEO, controller and the shift in the position of the CFO from part-time to full-time;
	●	an increase in professional services expenses due to the hiring of a financial consultant, HR consultant, the appointment of new directors and additional hires;

Operating loss

We incurred an operating loss of $6,250,000 for the nine months ended September 30, 2021, an increase of $2,777,000, or 80%, compared to operating loss of $3,473,000 for the nine months ended September 30, 2020. The increase in operating loss was due to $152,000 increase in gross loss, $836,000 increase in research and development expenses, and $170,000 increase in sales and marketing expenses and $1,622,000 increase in administrative and general expenses offset by $3,000 income from a sublease.

Cash Flows

The following table sets forth the significant sources and uses of cash for the periods set forth below (in dollars):

	Nine month ended September 30,
	2021			2020
Cash used in Operating Activity		(4,704,000	)		(2,710,000	)
Cash used in Investing Activity		(483,000	)		(249,000	)
Cash provided by Financing Activity		21,527,000			2,777,000

- 22 -

Operating Activities

For the nine months ended September 30, 2021, net cash flows used in operating activities was $4,704,000, due primarily to a net loss of $6,256,000, $504,000 increase in contract fulfilment assets partially offset by share based compensation of $1,317,000 and $529,000 increase in contract liabilities.

Investing Activities

For the nine months ended September 30, 2021, net cash flows used in investing activities was $483,000, due to the purchase of property and equipment.

Financing Activities

For the nine months ended September 30, 2021, net cash flows provided by financing activities was $21,527,000, due primarily to proceeds from the issuance of shares and warrants equivalent to approximately $19,118,000 and proceeds from exercise from warrants of approximately $2,459,000.

Comparison of the three months ended September 30, 2021 and 2020

The following table summarizes our results of operations for the three months period ended September 30, 2021, and 2020, together with the changes in those items in dollars and as a percentage:

	Three months ended September 30,
	2021			2020			% Change
Revenues		23,000			12,000			92	%
Cost of Revenues		211,000			153,000			38	%
Gross Loss		(188,000	)		(141,000	)		33	%
Research and development expenses		596,000			144,000			314	%
Sales and marketing expense		179,000			114,000			57	%
General and administrative expenses		1,603,000			629,000			155	%
Other income		3,000			-				%
Operating Loss		(2,563,000	)		(1,028,000	)		149	%

Revenues

For the three months ended September 30, 2021, we generated revenues of $23,000, an increase of $11,000 from the three months ended September 30, 2020.

Cost of Revenues

Cost of revenues for the three months ended September 30, 2021, was $211,000, an increase of $58,000 compared to cost of revenues of $153,000 for the three months ended September 30, 2020. The increase was primarily due to an increase in materials as a result of an increase in revenues and an increase in payroll expenses as a result of hiring additional employees as part of the transition to the production stage with respect to a contract with a Fortune 500 Multinational Healthcare Corporation.

Gross Loss

Gross loss for the three months ended September 30, 2021, was $188,000, an increase of $47,000 compared to gross loss of $141,000 for the three months ended September 30, 2020.

- 23 -

Research and Development Expenses

Research and development expenses for the three months ended September 30, 2021 were $596,000, an increase of $452,000, or 314%, compared to $144,000 for the three months ended September 30, 2020. The increase was primarily due to (i) an increase in payroll expenses, including increase in share based compensation (ii) materials and subcontractors; and (iii) an increase in research and development activities, including the development of new products and the improvement of existing technology. We recently began examining additional applications for our micro ScoutCam™ portfolio outside of the medical, defense and aerospace fields, including sectors such as automotive, industrial non-destructing-testing industries, and predictive maintenance (i.e. Industry 4.0) based on Internet of Things (IoT). We plan to further expand the activity in these non-medical spaces.

We expect that our research and development expenses will increase as we continue to develop our products and service, and recruit additional research and development employees.

Sales and Marketing Expenses

Sales and marketing expenses for the three months ended September 30, 2021 were $179,000, an increase of $65,000, or 57%, compared to $114,000 for the three months ended September 30, 2020. The increase was primarily due to expanded marketing activity, including the launching of a multi-platform digital marketing campaign.

General and Administrative Expenses

General and Administrative expenses for the three months ended September 30, 2021 were $1,603,000, an increase of $974,000, or 155%, compared to $629,000 for the three months ended September 30, 2020. The increase was primarily due to:

	●	an increase in in payroll expenses due to the hiring of additional employees including a new CEO, controller and the shift in the position of the CFO from part-time to full-time;
	●	an increase of $418,000 in share based compensation due to new option grants as described in Note 4 of our interim condensed financial statements as of September 30, 2021;
	●	the provision of $229,000 due to VAT audit as described in Note 9 of our interim condensed financial statements as of September 30, 2021.
	●	an increase in IP expenses due to maintenance, defense, and commercialization efforts of existing patents;
	●	an increase in professional services expenses due to the hiring of a financial consultant, HR consultant, the appointment of new directors and additional hires;

Operating loss

We incurred an operating loss of $2,563,000 for the three months ended September 30, 2021, an increase of $1,535,000, or 149%, compared to operating loss of $1,028,000 for the three months ended September 30, 2020. The increase in operating loss was due to $47,000 increase in gross loss, $452,000 increase in research and development expenses, and $65,000 increase in sales and marketing expenses and $974,000 increase in administrative and general expenses offset by $3,000 income from a sublease

Cash Flows

The following table sets forth the significant sources and uses of cash for the periods set forth below (in dollars):

	Three month ended September 30,
	2021			2020
Cash used in Operating Activity		(1,786,000	)		(433,000	)
Cash used in Investing Activity		(177,000	)		(28,000	)
Cash used in Financing Activity		(95,000	)		-

- 24 -

Operating Activities

For the three months ended September 30, 2021, net cash flows used in operating activities were $1,786,000, due primarily to a net loss of $2,562,000 partially offset by share based compensation of $682,000.

Investing Activities

For the three months ended September 30, 2021, net cash flows used in investing activities were $177,000 due to the purchase of property and equipment.

Future Funding Requirements

The Company believes that it will require additional financing in order to provide the capital it needs to achieve its growth targets.

Liquidity and Capital Resources

We generated liquidity primarily from fund raising and warrant exercises as described in Note 4 of our interim condensed financial statements as of September 30, 2021.

As of September 30, 2021, our total assets were $23,602,000. As of December 31, 2020, our total assets were $5,895,000. The increase of assets was mainly due to an increase of cash and cash equivalents due to fundraising activities and warrants exercise, as described in Note 4 of our interim condensed financial statements as of September 30, 2021.

As of September 30, 2021, our total liabilities were $3,000,000. As of December 31, 2020, our total liabilities were $1,931,000. The increase of liabilities was mainly due to an increase of accounts payables, contract liabilities and operating lease liabilities.

Since our incorporation through September 30, 2021, we incurred accumulated deficit of approximately $12.6 million. The management believes that our cash and cash resources as of September 30, 2021 will allow us to fund our operating plan through at least the next 12 months. However, we expect to continue to incur significant research and development expenses and other costs related to our ongoing operations; and in order to continue our future operations, we will need to obtain additional funding at least until such time that we become profitable.

Off-Balance Sheet Arrangements

None.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide the information requested by this Item.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Exchange Act Rule 13a-15(e). Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

No change in our internal control over financial reporting, as defined in Exchange Act Rule 13a-15(e), occurred during the fiscal quarter ended September 30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

- 25 -

PART II- OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows.

ITEM 1A. RISK FACTORS.

There have been no material changes from the information set forth in “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31,2020 as filed with the SEC on March 31, 2021.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES

There have been no unregistered sales of equity securities in addition to the sales provided under Form 8-K as filed with the SEC during the recent fiscal quarter ended September 30, 2021.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURE

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS.

(a) The following documents are filed as exhibits to this Quarterly Report or incorporated by reference herein.

Exhibit Number		Description
3.1.1		Amended and Restated Articles of Incorporation, effective as of August 9, 2021 (incorporated by reference to Exhibit 3.1.4 to our Quarterly Report on Form 10-Q filed with the SEC on August 12, 2021)

3.2.1		Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2.2 to our Quarterly Report on Form 10-Q filed with the SEC on August 12, 2021).

31.1*		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act

31.2*		Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act

32.1**		Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2**		Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		Inline XBRL Instance Document

101.INS		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

*		Filed herewith.

**		Furnished herewith.

- 26 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 15, 2021	SCOUTCAM INC.

	By:	/s/ Yovav Sameah
	Name:	Yovav Sameah
	Title:	Chief Executive Officer
		ScoutCam Inc.

	By:	/s/ Tanya Yosef
	Name:	Tanya Yosef
	Title:	Chief Financial Officer
		ScoutCam Inc.